NCT03539406View on ClinicalTrials.gov

Intraperitoneal Infusion of ex Vivo-cultured Allogeneic NK Cells in Recurrent Ovarian Carcinoma Patients

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 4, 2019

Primary Completion Date

May 1, 2023

Study Completion Date

September 1, 2023

Conditions

Recurrent Ovarian CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Primary Peritoneal Carcinoma

Interventions

BIOLOGICAL

UCB-NK cells

Intraperitoneal allogeneic UCB-NK cells infusion

DRUG

Chemotherapy

Cyclofosfamide/fludarabine treatment

Trial Locations (1)

Unknown

Radboudumc, Nijmegen

All Listed Sponsors

collaborator

Dutch Cancer Society

OTHER

lead

Radboud University Medical Center

OTHER

NCT03539406 - Intraperitoneal Infusion of ex Vivo-cultured Allogeneic NK Cells in Recurrent Ovarian Carcinoma Patients | Biotech Hunter | Biotech Hunter